Taysha Gene Therapies, Inc.

Historical 13F Holders

Symbol
TSHA
CUSIP
877619106
All holders as of
Q2 2026
Type
Equity
Class
COM SHS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 877619106 since 12/18/2024, newest first.

Filer % of Class Filed
RA Capital Management, L.P. 13G/A Amendment 5
9.9% 8/14/2026
Event 6/30/2026
Morgan Stanley 13G/A Amendment 2
5.1% 8/13/2026
Event 6/30/2026
RTW Investments, LP 13G/A Amendment 5
7.0% 5/15/2026
Event 3/31/2026
Vestal Point Capital, LP 13G/A Amendment 1
6.3% 5/15/2026
Event 3/31/2026
RTW Investments, LP 13G/A Amendment 4
8.3% 2/17/2026
Event 12/31/2025
Vestal Point Capital, LP 13G
5.0% 2/17/2026
Event 12/31/2025
FMR LLC 13G/A Amendment 10
4.9% 2/5/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 2 6.5% 1/21/2026
Event 12/31/2025
RA Capital Management, L.P. 13G/A Amendment 4
9.9% 11/14/2025
Event 9/30/2025
Octagon Capital Advisors LP 13G/A Amendment 1
3.3% 11/14/2025
Event 9/30/2025
RA Capital Management, L.P. 13G/A Amendment 3
9.9% 8/14/2025
Event 6/30/2025
RTW Investments, LP 13G/A Amendment 3
9.9% 8/14/2025
Event 6/30/2025
Morgan Stanley 13G/A Amendment 1
6.7% 8/6/2025
Event 6/30/2025
FMR LLC 13G/A Amendment 9
6.2% 8/6/2025
Event 6/30/2025
BlackRock, Inc. 13G/A Amendment 1 5.2% 7/16/2025
Event 6/30/2025
Goldman Sachs Group Inc 13G
5.1% 7/3/2025
Event 6/26/2025
Paul B Manning 13D/A Amendment 3
9.8% 6/3/2025
Event 5/30/2025
RTW Investments, LP 13G/A Amendment 2
10.0% 5/15/2025
Event 3/31/2025
RTW Investments, LP 13G/A Amendment 1
5.9% 2/14/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 8
8.0% 2/12/2025
Event 12/31/2024
Octagon Capital Advisors LP 13G
5.1% 2/5/2025
Event 12/31/2024
Morgan Stanley 13G
8.6% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 45.9 k $223 k
2026 Q2 217 301 M $2.23 B
2026 Q1 202 266 M $1.21 B
2025 Q4 210 269 M $1.48 B
2025 Q3 164 265 M $867 M
2025 Q2 156 263 M $609 M
2025 Q1 132 167 M $232 M
2024 Q4 136 167 M $290 M
2024 Q3 126 160 M $326 M
2024 Q2 114 169 M $378 M
2024 Q1 118 151 M $432 M
2023 Q4 96 130 M $231 M
2023 Q3 69 130 M $411 M
2023 Q2 42 13.7 M $9.05 M
2023 Q1 47 16.7 M $13.3 M
2022 Q4 57 19.5 M $44.0 M
2022 Q3 57 13.9 M $27.0 M
2022 Q2 61 14.7 M $54.7 M
2022 Q1 75 17.0 M $111 M
2021 Q4 66 18.5 M $216 M
2021 Q3 49 19.4 M $362 M
2021 Q2 51 18.6 M $395 M
2021 Q1 49 18.1 M $368 M
2020 Q4 53 18.0 M $475 M
2020 Q3 47 16.6 M $367 M